The effect of vitamin D status on risk factors for cardiovascular disease

Nature Reviews Nephrology

Volumn 9, Issue 6, 2013, Pages 337-347

  Gunta, Sujana S ^a   Thadhani, Ravi I ^b   Mak, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 6; OMEGA 3 FATTY ACID; PARATHYROID HORMONE; PARICALCITOL; RENIN; VITAMIN D;

ANGIOTENSIN BLOOD LEVEL; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW (TOPIC); VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

CARDIOVASCULAR DISEASES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84878578759     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.74     Document Type: Review

References (121)

1. Hewison, M. et al. Extra-renal 25-hydroxyvitamin D3 1α hydroxylase in human health and disease. J. Steroid Biochem. Mol. Biol. 103, 316-321 (2007).
2. Holick, M. F. Vitamin D deficiency. N. Engl. J. Med. 357, 266-281 (2007).
3. Holick, M. F. et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911-1930 (2011).
4. Clements, M. R. et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin. Endocrinol. (Oxf.) 37, 17-27 (1992).
5. Jones, G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 88, 582S-586S (2008).
6. Gordon, C. M., DePeter, K. C., Feldman, H. A., Grace, E. & Emans, S. J. Prevalence of vitamin D deficiency among healthy adolescents. Arch. Pediatr. Adolesc. Med. 158, 531-537 (2004).
7. Sullivan, S. S., Rosen, C. J., Halteman, W. A., Chen, T. C. & Holick, M. F. Adolescent girls in Maine at risk for vitamin D insufficiency. J. Am. Diet Assoc. 105, 971-974 (2005).
8. Nesby O'Dell, S. et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Clin. Nutr. 76, 187-192 (2002).
9. Tangpricha, V., Pearce, E. N., Chen, T. C. & Holick, M. F. Vitamin D insufficiency among free-living healthy young adults. Am. J. Med. 112, 659-662 (2002).
10. Bischoff-Ferrari, H. A. et al. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA. 293, 2257-2264 (2005).
11. Boonen, S. et al. Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: A review of the evidence. Calcif. Tissue Int. 78, 257-270 (2006).
12. Hollis, B. W. & Wagner, C. L. Normal serum vitamin D levels. N. Engl. J. Med. 352, 515-516 (2005).
13. Pilz, S. et al. Vitamin D, cardiovascular disease and mortality. Clin. Endocrinol. (Oxf). 75, 575-584 (2011).
14. Anderson, J. L. et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am. J. Cardiol. 106, 963-968 (2010).
15. Zhao, G., Ford, E. S., Li, C & Croft, J. B. Serum 25-hydroxyvitamin D levels and all-cause and cardiovascular disease mortality among US adults with hypertension: The NHANES linked mortality study. J. Hypertens. 30, 284-289 (2012).
16. Institute of Medicine of the National Academies. Dietary Reference Intakes for Calcium and Vitamin D. [online], http://www.iom.edu/~/media/Files/ Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/ VitaminDand20Calcium2010ReportBrief.pdf (2013).
17. Li, Y. C. et al. 25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110, 229-238 (2002).
18. Xiang, W. et al. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 288, E125-E132 (2005).
19. Zhou, C. et al. Calcium-independent and 25(OH)2D3-dependent regulation of the renin-angiotensin system in 1-α-hydroxylase knockout mice. Kidney Int. 74, 170-179 (2008).
20. Tiosano, D. et al. The renin-angiotensin system, blood pressure, and heart structure in patients with hereditary vitamin D resistance rickets (HVDRR). J. Bone Miner. Res. 26, 2252-2260 (2011).
21. Forman, J. P., Williams, J. S. & Fisher, N. D. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 55, 1283-1288 (2010).
22. Zhang, Y. et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase 1. J. Immunol. 188, 2127-2135 (2012).
23. Canning, M. O., Grotenhuis, K., de Wit, H., Ruwhof, C. & Drexhage, H. A. 1 α,25-Dihydroxyvitamin D3 (25(OH)2D3) hampers the maturation of fully active immature dendritic cells from monocytes. Eur. J. Endocrinol. 145, 351-357 (2001).
24. Zhu, Y., Mahon, B. D., Froicu, M. & Cantorna, M. T. Calcium and 1α, 25-dihydroxyvitamin D3 target the TNF-α pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol. 35, 217-224 (2005).
25. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
26. Adams, D. H. & Shaw, S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 343, 831-836 (1994).
27. Zehnder, D. et al. Synthesis of 1,25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 13, 621-629 (2002).
28. Suzuki, Y. et al. Anti-inflammatory effect of 1-α,25- dihydroxyvitamin D3 in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. J. Steroid Biochem. Mol. Biol. 113, 134-138 (2009).
29. Dusso, A., Arcidiacono, M. V., Yang, J. & Tokumoto, M. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J. Steroid Biochem. Mol. Biol. 121, 193-198 (2010).
30. Gupta, G. K., Agrawal, T., Delcore, M. G., Mohiuddin, S. M. & Agrawal, D. K. Vitamin D deficiency induces cardiac hypertrophy and inflammation in epicardial adipose tissue in hypercholesterolemic swine. Exp. Mol. Pathol. 93, 82-90 (2012).
31. Takeda, M. et al. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler. Thromb. Vasc. Biol. 30, 2495-2503 (2010).
32. Räisänen-Sokolowski, A. K. et al. A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation 63, 936-941 (1997).
33. Torre-Amione, G. et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 93, 704-711 (1996).
34. Ahmad, S. et al. Decreased myocardial expression of dystrophin and titin mRNA and protein in dilated cardiomyopathy: Possibly an adverse effect of TNF-α. J. Clin. Immunol. 30, 520-530 (2010).
35. Rauchhaus, M. et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102, 3060-3067 (2000).
36. Yadav, A. K., Banerjee, D., Lal, A. & Jha, V. Vitamin D deficiency, CD4(+)CD28(null) cells and accelerated atherosclerosis in chronic kidney disease. Nephrology (Carlton) 17, 575-581 (2012).
37. Prietl, B. et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: Vitamin D treatment for autoimmune diseases? Isr. Med. Assoc. J. 12, 136-139 (2010).
38. Caprio, M., Mammi, C. & Rosano, G. M. Vitamin D: A novel player in endothelial function and dysfunction. Arch. Med. Sci. 8, 4-5 (2012).
39. Tarcin, O. et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J. Clin. Endocrinol. Metab. 94, 4023-4030 (2009).
40. Raymond, M. A. et al. Endothelial stress induces the release of vitamin D binding protein, a novel growth factor. Biochem. Biophys. Res. Commun. 338, 1374-1382 (2005).
41. Aihara, K. et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Biol. Chem. 279, 35798-35802 (2004).
42. Wu-Wong, J. R., Nakane, M. & Ma, J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor 1, thrombospondin 1 and thrombomodulin in human aortic smooth muscle cells. J. Vasc. Res. 44, 11-18 (2007).
43. Giachelli, C. M. et al. Vascular calcification and inorganic phosphate. Am. J. Kidney Dis. 38, S34-S37 (2001).
44. Jono, S. et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 87, E10-E17 (2000).
45. Tintut, Y., Patel, J., Parhami, F. & Deemer, L. L. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102, 2636-2642 (2000).
46. Giachelli, C. M. Vascular calcification: In vitro evidence for the role of inorganic phosphate. J. Am. Soc. Nephrol. 14, S300-S304 (2003).
47. Aoshima, Y. et al. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF α. Nephrol. Dial.Transplant. 27, 1800-1806 (2012).
48. Mizobuchi, M., Finch, J. L., Martin, D. R. & Slatopolsky, E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 72, 709-715 (2007).
49. Chitalia, N., Recio-Mayoral, A., Kaski, J. C. & Banerjee, D. Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis 220, 265-268 (2012).
50. London, G. M. et al. Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J. Am. Soc. Nephrol. 18, 613-620 (2007).
51. Yiu, Y. F. et al. Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 96, E830-E835 (2011).
52. Jablonski, K. L., Chonchol, M., Pierce, G. L., Walker, A. E. & Seals, D. R. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 57, 63-69 (2011).
53. Al Mheid, I. et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J. Am. Coll. Cardiol. 58, 186-192 (2011).
54. Bodyak, N. et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc. Natl Acad. Sci. USA 104, 16810-16815 (2007).
55. Chen, S. et al. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 124, 1838-1847 (2011).
56. Sanna, B. et al. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc. Natl Acad. Sci. USA 103, 7327-7332 (2006).
57. Ornitz, D. M. FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 22, 108-112 (2000).
58. Wolf, M. Forging forward with 10 burning questions on FGF23 in kidney disease. J. Am. Soc. Nephrol. 21, 1427-1435 (2010).
59. Gutiérrez, O. M. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: Updating the "trade-off" hypothesis. Clin. J. Am. Soc. Nephrol. 5, 1710-1716 (2010).
60. Ornitz, D. M. & Itoh, N. Fibroblast growth factors. Genome Biol. 2, 1-12 (2001).
61. Shimada, T. et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl Acad. Sci. USA 98, 6500-6505 (2001).
62. Gutiérrez, O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584-592 (2008).
63. Parker, B. D. et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann. Intern. Med. 152, 640-648 (2010).
64. Gutierrez, O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584-592 (2008).
65. Kendrick, J. et al. FGF 23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 22, 1913-1922 (2011).
66. Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408 (2011).
67. Liu, S. et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin, D. J. Am. Soc. Nephrol. 17, 1305-1315 (2006).
68. Wetmore, J. B., Liu, S., Krebill, R., Menard, R. & Quarles, L. D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin. J. Am. Soc. Nephrol. 5, 110-116 (2010).
69. Nishi, H. et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor 23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin. Pract. 101, c94-c99 (2005).
70. Querfeld, U. & Mak, R. H. Vitamin D deficiency and toxicity in chronic kidney disease: In search of the therapeutic window. Pediatr. Nephrol. 25, 2413-2430 (2010).
71. Scragg, R., Sowers, M. & Bell, C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am. J. Hypertens. 20, 713-719 (2007).
72. Zhao, G. et al. Independent associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with blood pressure among US adults. J. Hypertens. 28, 1821-1828 (2010).
73. Forman, J. P., Curhan, G. C. & Taylor, E. N. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 52, 828-832 (2008).
74. Forman, J. P. et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49, 1063-1069 (2007).
75. Feneis, J. F. & Arora, R. R. Role of vitamin D in blood pressure homeostasis. Am. J. Ther. 17, e221-e229 (2010).
76. Burgaz, A., Orsini, N., Larsson, S. C. & Wolk, A. Blood 25-hydroxyvitamin D concentration and hypertension: A meta-analysis. J. Hypertens. 29, 636-645 (2011).
77. Fiscella, K. & Franks, P. Vitamin D, race, and cardiovascular mortality: Findings from a national US sample. Ann. Fam. Med. 8, 11-18 (2010).
78. Giovannucci, E., Liu, Y., Hollis, B. W. & Rimm, E. B. 25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch. Intern. Med. 168, 1174-1180 (2008).
79. Kilkkinen, A. et al. Vitamin D status and the risk of cardiovascular disease death. Am. J. Epidemiol. 170, 1032-1039 (2009).
80. Pilz, S. et al. Vitamin D and mortality in older men and women. Clin. Endocrinol. (Oxf.) 71, 666-672 (2009).
81. Semba, R. D. et al. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. Eur. J. Clin. Nutr. 64, 203-209 (2010).
82. Wang, T. J. et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503-511(2008).
83. Grandi, N. C., Breitling, L. P. & Brenner, H. Vitamin D and cardiovascular disease: Systematic review and meta-analysis of prospective studies. Prev. Med. 51, 228-233 (2010).
84. Zittermann, A. et al. Vitamin D deficiency and mortality risk in the general population: A meta-analysis of prospective cohort studies. Am. J. Clin. Nutr. 95, 91-100 (2012).
85. Pilz, S., Lodice, S., Zittermann, A., Grant, W. B. & Gandini, S. Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am. J. Kidney Dis. 58, 374-382 (2011).
86. Pittas, A. G. et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 152, 307-314 (2010).
87. Wang, A. Y. et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: A 3 y prospective cohort study. Am. J. Clin. Nutr. 87, 1631-1638 (2008).
88. Blacher, J., Guerin, A. P., Pannier, B., Marchais, S. J. & London, G. M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38, 938-942 (2001).
89. London, G. M. et al. Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J. Am. Soc. Nephrol. 18, 613-620 (2007).
90. Shroff, R. et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J. Am. Soc. Nephrol. 19, 1239-1246 (2008).
91. Barreto, D. V. et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1128-1135 (2009).
92. Wolf, M. et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 72, 1004-1013 (2007).
93. Ravani, P. et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 75, 88-95 (2009).
94. Mattila, C. et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 30, 2569-2570 (2007).
95. Joergensen, C. et al. Vitamin D levels and mortality in type 2 diabetes. Diabetes Care 33, 2238-2243 (2010).
96. Forouhi, N. G., Luan, J., Cooper, A., Boucher, B. J. & Wareham, N. J. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: The Medical Research Council Ely Prospective Study 1990-2000. Diabetes 57, 2619-2625 (2008).
97. Mitri, J., Muraru, M. D. & Pittas, A. G. Vitamin D and type 2 diabetes: A systematic review. Eur. J. Clin. Nutr. 65, 1005-1015 (2011).
98. Sun, Q., Pan, A., Hu, F. B., Manson, J. E. & Rexrode, K. M. 25-Hydroxyvitamin D levels and the risk of stroke: A prospective study and meta-analysis. Stroke 43, 1470-1477 (2012).
99. Pilz, S. et al. Vitamin D supplementation: A promising approach for the prevention and treatment of strokes. Curr. Drug Targets. 12, 88-96 (2011).
100. Schleithoff, S. S. et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 83, 754-759 (2006).
101. Bucharles, S. et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J. Ren. Nutr. 22, 284-291(2012).
102. Shab-Bidar, S. et al. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab. Res. Rev. 28, 424-430 (2012).
103. Witham, M. D., Nadir, M. A. & Struthers, A. D. Effect of vitamin D on blood pressure: A systematic review and meta-analysis. J. Hypertens. 27, 1948-1954 (2009).
104. Wu, S. H., Ho, S. C. & Zhong, L. Effects of vitamin D supplementation on blood pressure. South Med. J. 103, 729-737 (2010).
105. Lishmanov, A., Dorairajan, S., Pak, Y., Chaudhary, K. & Chockalingam, A. Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events. Am. J. Ther. http://dx.doi.org/10.1097/MJT.0b013e3182211b3b.
106. Kim, H. W. et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin. Pract. 102, c21-c29 (2006).
107. Park, C. W. et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 33, 73-81 (1999).
108. Mak, R. H. Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. Pediatr. Nephrol. 6, 345-348 (1992).
109. Thadhani, R. et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307, 674-684 (2012).
110. Tamez, H. et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am. Heart J. 164, 902-909 (2012).
111. Kandula, P. et al. Vitamin D supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Clin. J. Am. Soc. Nephrol. 6, 50-62 (2011).
112. Saliba, W. & El-Haddad, B. Secondary hyperparathyroidism: Pathophysiology and treatment. J. Am. Board Fam. Med. 22, 574-581 (2009).
113. Fukagawa, M., Nakanishi, S. & Kazama, J. J. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int. Suppl. 102, S3-S7 (2006).
114. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 113, S1-S130 (2009).
115. Gal-Moscovici, A. & Sprague, S. M. Use of vitamin D in chronic kidney disease patients. Kidney Int. 78, 146-151 (2010).
116. Elamin, M. B. et al. Vitamin D and cardiovascular outcomes: A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 1931-1942 (2011).
117. Bjelakovic, G. et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Systematic Reviews, Issue 7. Art. No.:CD007470. http//dx.doi.org/10.1002/14651858.CD007470.pub2 (2011).
118. Witte, K. K. et al. The effect of micronutrient supplementation on quality of life and left ventricular function in elderly patients with chronic heart failure. Eur. Heart J. 26, 2238-2244 (2005).
119. Witham, M. D. et al. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: A randomised controlled trial. Diabetologia 53, 2112-2119 (2010).
120. Sugden, J. A., Davies, J. I., Witham, M. D., Morris, A. D. & Struthers, A. D. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 25, 320-325 (2008).
121. Manson, J. et al. The VITamin D and omega 3 triaL (VITAL). Contemp. Clin. Trials 33, 159-171 (2012).